These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21557834)

  • 1. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
    Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
    Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
    N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
    Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
    Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
    Shaw GL; Hussain M; Nair R; Bycroft J; Beltran L; Green JS; Powles T; Peters JL
    Urol Int; 2012; 89(1):83-8. PubMed ID: 22614181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
    Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
    Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
    Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
    World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
    Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
    Biswas S; Kelly J; Eisen T
    Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy for Renal Cell Carcinoma.
    Joshi R; Rawal S
    JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma.
    Locatelli MC; Miedico A; D'Antona A; Longo G; Maggioni M; Maggioni A; Tombolini P; Tabiadon D
    Tumori; 2010; 96(3):478-82. PubMed ID: 20845812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
    Lainakis G; Bamias A; Psimenou E; Fountzilas G; Dimopoulos MA
    Clin Nephrol; 2009 Jul; 72(1):73-8. PubMed ID: 19640391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
    Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
    Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-surgical targeted molecular therapy in renal cell carcinoma.
    Margulis V; Wood CG
    BJU Int; 2009 Jan; 103(2):150-3. PubMed ID: 19007359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
    Rini BI; Garcia J; Elson P; Wood L; Shah S; Stephenson A; Salem M; Gong M; Fergany A; Rabets J; Kaouk J; Krishnamurthi V; Klein E; Dreicer R; Campbell S
    J Urol; 2012 May; 187(5):1548-54. PubMed ID: 22425095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
    Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
    World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.